ASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTSASSOCIATION OF SUBCLINICAL HYPOTHYROIDISM IN METABOLIC SYNDROME PATIENTS

Jennifer S Suhashini; Savitha G

doi:10.22159/ajpcr.2018.v11i9.26734

Authors

Jennifer S Suhashini Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.
Savitha G Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.

DOI:

https://doi.org/10.22159/ajpcr.2018.v11i9.26734

Keywords:

Metabolic syndrome, Sub-clinical hypothyroidism, Central adiposity, Hypertriglyceridemia, Impaired glucose tolerance

Abstract

Objectives: Subclinical hypothyroidism (SCH) is also the major risk for cardiovascular disease like metabolic syndrome (MetS). Hence, the aim of this study is to assess the association of SCH in MetS patients.

Materials and Methods: Ninety patients reporting to Saveetha Dental College and Hospitals were enrolled in the study which includes 40 patients with MetS and 40 healthy individuals. 5 ml of venous blood was collected and centrifuged. Then, it is analyzed for fasting blood sugar, serum triglycerides, high-density lipoprotein cholesterol (HDL-c), low-density lipoprotein cholesterol (LDL-c), and very low-density lipoprotein (VLDL) using the standard kit method. Then, Free T3, Free T4, and thyroid-stimulating hormone (TSH) were estimated by ELISA method. The data obtained were subjected to statistical analysis using the SPSS software.

Results: SCH is 20% in cases when compared to 4.4% in controls, which was significant, p=0.024. The biochemical parameters were compared between the study population fasting blood glucose, triglycerides, total cholesterol, low-density lipoprotein cholesterol, and VLDL cholesterol was statistically significant, with p<0.001. TSH levels showed significant difference between two groups with the p=0.002.

Conclusion: MetS patients should be screened for the SCH as an important risk factor in evaluation protocol. Mere correction of TSH levels can reverse the associated morbidity in these patients rather than leaving them untreated pushing them to a state of overt hypothyroidism with its attendant complications.

Downloads

Download data is not yet available.

Author Biography

Jennifer S Suhashini, Department of Biochemistry, Saveetha Dental College, Saveetha Institute of Medical and Technical Sciences, Saveetha University, Chennai, Tamil Nadu, India.

Department of Biochemistry

References

Shantha GP, Kumar AA, Jeyachandran V, Rajamanickam D, Rajkumar K, Salim S, et al. Association between primary hypothyroidism and metabolic syndrome and the role of C reactive protein: A cross-sectional study from south India. Thyroid Res 2009;2:2.

Mohan V, Deepa M, Farooq S, Datta M, Deepa R. Prevalence, awareness and control of hypertension in Chennai â€“ The Chennai urban rural epidemiology study (CURES-52). J Assoc Physicians India 2007;55:326-32.

Gupta R, Deedwania PC, Gupta A, Rastogi S, Panwar RB, Kothari K. Prevalence of metabolic syndrome in an Indian urban population. Int J Cardiol 2004;97:257-61.

Kylin E. Studies of the hypertension-hyperglycemia-hyperuricemia syndrome (German). Zentralbl Inn Med 1923;44:105-27.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988;37 Suppl 12:1595-607.

Nerkar D, Mukherjee A, Mehta BM, Banerjee S. Metabolic syndrome associated complications. Int J Pharm Pharm Sci 2015;7 Suppl 7:22-5.

Guru EP, Savitha G. Prevalence of coronary atherosclerotic heart disease in metabolic syndrome patients. J Pharm Sci Res 2015;7 Suppl 9:724-6.

Agarwal G, Sudhakar MK, Singh M, Senthil N, Sajendran AR. The prevalence of thyroid dysfunction among South Indian women with metabolic syndrome. J Clin Diag Res 2012;5:213-6.

Pearce EN. Update in lipid alterations in subclinical hypothyroidism. J Clin Endocrinol Metab 2012;97 Suppl 2:326-33.

Fatourechi V. Subclinical hypothyroidism: An update for primary care physicians. Mayo Clin Proc 2009;84 Suppl 1:65-71.

Lewis GF, Carpentier A, Adeli K, Giacca A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr Rev 2002;23:201-29.

Lam TK, Carpentier A, Lewis GF, van de Werve G, Fantus IG, Giacca A, et al. Mechanisms of the free fatty acid-induced increase in hepatic glucose production. Am J Physiol Endocrinol Metab 2003;284:E863 73.

de Lloyd A, Bursell J, Gregory JW, Rees DA, Ludgate M. TSH receptor activation and body composition. J Endocrinol 2010;204:13-20.

de Moura Souza A, Sichieri R. Association between serum TSH concentration within the normal range and adiposity. Eur J Endocrinol 2011;165:11-5.

Tehrani FR, Tohidi M, Dovom MR, Azizi F. A population based study on the association of thyroid status with components of the metabolic syndrome. J Diabetes Metab 2011;2 Suppl 8:156.

Antunes TT, Gagnon AM, Bell A, Sorisky A. Thyroid-stimulating hormone stimulates interleukin-6 release from 3T3-L1 adipocytes through a cAMP-protein kinase A pathway. Obesity Res 2005;13 Suppl 12:2066-71.

Al-Biati HA, Sahib AS, Ismail SH. Effects of metformin and glibenclamide combination in Iraqi obese patients with metabolic syndrome. Int J Pharm Pharm Sci 2014;6 Suppl 10:501-3.

Lai Y, Wang J, Jiang F, Wang B, Chen Y, Li M, et al. The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J 2011;58:23-30.

Gagnon A, Antunes TT, Ly T, Pongsuwan P, Gavin C, Lochnan HA, et al. Thyroid-stimulating hormone stimulates lipolysis in adipocytes in culture and raises serum free fatty acid levels in vivo. Metabolism 2010;59:547-53.